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HO = heme oxygenase; NO = nitric oxide.
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Abstract
Statins have a variety of properties that are independent of their
lipid lowering ability. These anti-inflammatory, antioxidant, immuno-
modulatory, and antiapoptotic features have been collectively
referred to as pleiotropic effects. Severe sepsis is an intense
infection-induced inflammatory syndrome that ultimately results in
organ dysfunction. Because so many cascades are triggered
during sepsis, merely blocking a single component may be
insufficient to arrest the inflammatory process. A growing body of
evidence suggests that statins may indeed have a protective effect
against severe sepsis and reduce the rate of infection-related
mortality. This novel primary prevention concept may have far-
reaching implications for the future management of serious
infections. Moreover, it was recently shown that statins potentially
improve outcome after the onset of sepsis. The stage is now set for
randomized clinical trials that will determine the precise role, if any,
that statins may have in preventing and treating sepsis.
Severe sepsis is an infection-induced inflammatory syndrome
that ultimately leads to organ dysfunction. It is estimated that
more than 500,000 episodes of sepsis occur each year in the
USA alone, and that 20–50% of these patients will die [1].
Disturbingly, the incidence of sepsis and number of sepsis-
related deaths appear to be increasing [1]. Important
progress has been made in recent years, and interventions
such as activated protein C, early goal-directed therapy, and
possibly low-dose corticosteroids have been shown to
improve survival in patients with severe sepsis [2]. Despite
these advances, mortality remains unacceptably high and
care for patients with sepsis costs as much as $50,000 per
patient, resulting in an economic burden of nearly $17 billion
annually in the USA alone [1].
It is generally accepted that sepsis syndrome reflects the
delicate balance between extensive triggering of defense
mechanisms by invading micro-organisms and both direct
and indirect effects of these micro-organisms and their
products. Most investigators would agree that severe sepsis
is accompanied by the inability to regulate the inflammatory
response and that the cause of this perturbation is still not
well defined [2]. In fact, Sir William Osler, some 100 years
ago, suggested that, ‘Except on few occasions the patient
appears to die from the body’s response to infection rather
than from it’ [3]. Over the past 3 decades, numerous trials
have failed to demonstrate that blocking specific inflammatory
mediators is beneficial in sepsis. Despite this frustration, new
strategies are being explored such as blockade of high-
mobility group B1 protein, macrophage migration inhibitory
factor, and the complement split product C5a [2]. However,
in complex situations such as severe sepsis, multiple cellular
activation processes are involved and many humoral
cascades are triggered, and so merely blocking a single
component may be insufficient to arrest the inflammatory
process [4]. Given the acute onset and unpredictable nature
of sepsis, primary prevention has not been within the thinking
paradigm of this syndrome.
Statins have a wide variety of properties that are independent
of their lipid-lowering ability. These anti-inflammatory, anti-
oxidant, immunomodulatory, antiapoptotic, antiproliferative,
antithrombotic, and endothelium protecting features have
been collectively referred to as pleiotropic effects [5]. A large
and growing body of knowledge supports the notion that
statins may be beneficial in preventing and possibly treating
sepsis (Fig. 1) [4].
Microbial products recognized by phagocytic leukocytes and
other immune cells form the molecular basis for the beginning
of the sepsis syndrome. This process is accomplished by a
variety of receptors that identify pathogen-associated
conserved motifs. There are data suggesting that statins may
interfere with this receptor–ligand interaction, thus blunting
the first step in the activation of the cellular cascade [6].
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The acute phase response includes a wide variety of
mediators such as C-reactive protein, cytokines, and others.
Their precise role in response to infection has not been fully
elucidated. Extrapolating primarily from studies conducted in
atherosclerosis, it is well known that statins markedly
decrease these inflammatory markers [7]. Blunting this mal-
adaptive exaggerated inflammatory response may be beneficial
in sepsis.
Numerous studies using different models have demonstrated
convincingly that statin pretreatment improves endothelial
dysfunction, blunts apoptosis, and decreases levels of pro-
inflammatory cytokines, chemokines, and adhesion molecules.
The antithrombotic effects of statins may also ameliorate
sepsis-induced coagulopathy [5,8,9]. Another novel pathway
may play an important role in attenuating sepsis-induced
endothelial dysfunction. Heme oxygenase (HO)-1 is an
inducible, heat shock cytoprotective protein. Simvastatin
activates and increases HO-1 in a concentration-dependent
and time-dependent manner. This induction was observed in
vascular smooth muscle and endothelial cells both in vitro
and  in vivo, suggesting that the anti-inflammatory, anti-
proliferative, and antioxidant effects of simvastatin occur
largely through induction of HO-1 [10,11].
An increase in nitric oxide (NO) production contributes to the
hypotension and resistance to vasopressor therapy that
occur in sepsis. Ample data using various models indicate
that statins profoundly affect NO availability [5,12-14].
Specifically, in a rat pretreatment model simvastatin
decreased NO overproduction and reverted the impaired
vascular responsiveness induced by endotoxic shock [14].
Moreover, vascular hyporeactivity and peripheral vaso-
dilatation are central characteristics of severe sepsis. In a
randomized, placebo-controlled study in healthy volunteers
challenged by lipopolysaccharide-induced inflammation,
simvastatin exhibited potent vasoprotective properties [15].
An additional key characteristic of the hemodynamic
perturbation in sepsis is myocardial dysfunction. In a pivotal
report [16], mice pretreated with simvastatin and rendered
septic by cecal ligation and perforation were found to exhibit
a mean survival time close to four times that in untreated
control animals. Complete preservation of cardiac function
and hemodynamic status was observed [16]. Furthermore, in
a similar study [17], in which treatment with various statins or
placebo was initiated 6 hours after sepsis induction, when
profound hemodynamic alterations were already evident,
survival time was again significantly extended in treated
Figure 1
Key events leading from infection to multiorgan failure. For the sake of clarity, not all interactions and pathways are shown. ‘S’ denotes possible
sites where statins might be exerting their beneficial effect. Shown in italics are some of the main clinical manifestations pertinent to specific
elements of the inflammatory cascade. CRP, C-reactive protein; DIC, disseminated intravascular coagulation; HO, heme oxygenase; NO, nitric
oxide; SIRS, systemic inflammatory response syndrome.Page 3 of 3
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animals and hemodynamic status was markedly improved.
The importance of this latter report is further highlighted by its
being the first to propose that statins may be beneficial as a
therapeutic modality after the onset of sepsis-induced organ
dysfunction.
Data in humans are lacking. In a prospective observational
cohort study [18] it was found that prior statin therapy is
associated with a decreased rate of severe sepsis and
intensive care unit admission in patients admitted with acute
bacterial infections. Even though this observational study was
not powered to detect differences in sepsis-related mortality,
a trend toward reduction in mortality was observed. In
another large, community-based prospective study in which
11,362 patients were followed for up to 3 years (Almog and
coworkers, unpublished data), we observed that therapy with
statins may be associated with a reduced rate of infection-
related mortality. This protective effect was independent of
comorbidities and dissipated when the medication was
discontinued.
There is growing interest among clinicians in the role that
statins may play in preventing and treating serious infections.
If such an effect of statins can be supported by randomized
controlled clinical trials, then the implications could be far
reaching. The stage is set for trials that will determine the
precise role, if any, of statins in the primary prevention and
treatment of this lethal yet potentially reversible syndrome.
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